PARALLEL SESSION 1 // NEUROMUSCULAR JUNCTION

2:30 PM • S18L1 • Emerging therapies for autoimmune myasthenia gravis > J. Jan VERSCHUUREN (Amsterdam, The Netherlands) 3:00 PM • S18L2 • Moving towards personalized medicine in Myasthenia Gravis through biomarkers and the power of physical exercise > A. Anna PUNGA (Uppsala, Sweden) 3:30 PM • S18L3 • Origin of the thymic interferon type I signature in myasthenia Gravis: role of endogenous nucleic acids > R. Rozen LE PANSE (Paris, France) 3:45 PM • S18L4 • Concomitant Corticosteroid Use in Ravulizumab-Treated Adults With Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-label Extension > D. Djillali ANNANE (Paris, France)